Archive

Formycon AG has today announced its results for the first nine months of the 2022 fiscal year.

Formycon AG has today published preclinical in vivo results for the development of their COVID-19 drug FYB207.

Formycon AG today published its half-year report 2022, confirming the preliminary operating figures for the first half of 2022 already announced on September 06, 2022.

Formycon AG today announced details of a previously undisclosed project in its development pipeline. FYB206 is a biosimilar candidate for Keytruda® (pembrolizumab) and the development is at an advanced preclinical stage.

Formycon AG today announced its preliminary and unaudited financial figures for the first half of 2022. Reporting at Group level is performed for the first time in accordance with IFRS (International Financial Reporting Standards).

Formycon AG, Polpharma Biologics Group BV and Bioeq AG jointly announce that the European Commission has granted marketing authorization for Ranivisio® (Ranivisio - Ranibizumab), a biosimilar to Lucentis® (ranibizumab-injection), for the treatment for several serious retinal diseases in the European Union.

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the European Comission (“EC”) today has granted marketing authorization (“MA”) for Ranivisio®, a biosimilar to Lucentis® (ranibizumab-injection) for medical use in the European Union (“EU”).

Formycon AG today reported positive preliminary efficacy and safety data from VESPUCCI Phase III clinical trial for FYB202, its proposed biosimilar version of Stelara®(Ustekinumab).

CIMERLI™ is the first and only interchangeable biosimilar with an exclusivity of 12 month after market launch that is indicated for the treatment of all five Lucentis® indications and as such is a new medical option for patients with serious retinal diseases.

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announces that the U.S. Food and Drug Administration (“FDA”) has approved CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection).

FYB201 was developed by Bioeq AG, a Joint...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its Annual General Meeting on June 30, 2022 in virtual form.

Munich – Based on the resolution of the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) dated June 27, 2022, the election proposal under agenda item 9 of the agenda for the 2022 Annual General Meeting of Formycon AG published in the Federal Gazette on May 20, 2022 shall be...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") announce that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") today issued a positive opinion for FYB201, a biosimilar to...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today presented the sales and earnings figures for the first quarter of 2022, demonstrating a start to the financial year that meets expectations.

Group turnover including other income amounted to a total of EUR 8.2 million as March 31,...

Munich – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) („Formycon“) today announced an update on their development projects.

FYB201, Formycons biosimilar to Lucentis® (ranibizumab), was recently approved by the British Medicines Agency MHRA (Medicines and Healthcare products...

Munich – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") today announced changes to its Executive Board, setting the stage for continued and stable leadership as the company moves towards becoming a global and fully integrated biosimilars pharmaceutical company.

Today and...

Munich – Today and effective July 1, 2022, the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") appointed Dr. Stefan Glombitza, who has led Formycon's operational development activities as Chief Operating Officer (COO) since 2016, as Chief Executive Officer...

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today released its financials for 2021.

The focus in 2021 was on the further development of the current biosimilar candidates as well as the COVID-19 drug (FYB207). The development activities of the late-stage biosimilar projects...

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce, that today the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) in the United Kingdom (“UK”) for FYB201, a biosimilar to...

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce, that today the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization (MA) in the United Kingdom (“UK”) for FYB201, a biosimilar to...

Munich – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Formycon”) and ATHOS KG (“ATHOS”) announce the closing of the acquisition of the biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH ("Bioeq") with the registration of the implementation of the non-cash capital increase in...

The transaction creates key enablers for further expanding Formycon’s position as a company operating on the global stage in the growth market for biosimilars

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and SCG Cell Therapy Pte Ltd ("SCG") today announced that they have entered into a collaboration and license agreement for the development and commercialization of Formycon's proprietary COVID-19 drug FYB207. Under the terms of the agreement,...

Munich - Bioeq AG ("Bioeq"), licensee and exclusive holder of the worldwide commercialization rights for FYB201, Formycon's biosimilar candidate for Lucentis(R) (ranibizumab), has informed Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) that it has entered into an exclusive partnership with MS...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), together with its academic partners Prof. Dr. Ulrike Protzer, Chair of Virology, and Prof. Dr. Johannes Buchner, Chair of Biotechnology, Technical University of Munich (TUM), today announced the publication of new in vitro data on the...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today announced its results for the first nine month of the 2021 fiscal year.

The key financial figures of the Formycon Group also developed as expected at the end of the third quarter. Turnover within the Group which, alongside the...

“We are very glad about the collaboration with SCG which allows us to accelerate the development and commercialization of our COVID-19 drug FYB207 in the most populated region of the world”, says Dr. Carsten Brockmeyer, CEO of Formycon

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and SCG Cell Therapy Pte Ltd ("SCG") today announced that they have entered into a collaboration and license agreement for the development and commercialization of Formycon's proprietary COVID-19 drug FYB207. Under the terms of the agreement,...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce that the U.S. Food and Drug Administration (FDA) accepted the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis®1, for review and assigned a target action date for the application for August 2022.

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its Annual General Meeting on September 27, 2021 - for the protection of all persons involved - in virtual form.

The shareholders were able to follow the virtual Annual General Meeting live in picture and sound via the Company's...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today announced its financial results for the first half of 2021.

On the day of reporting, June 30, 2021, the Formycon Group's financial figures were as forecast. Turnover within the Group which, alongside the joint-stock company...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB207.

For what is now the 22nd time, the Pharma Trend Image &...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today provided an update on the development status of its COVID-19 drug FYB207.

SARS-CoV-2 and other coronaviruses use the protein ACE2 on the surface of human cells as a portal of entry for respiratory infections. Formycon has...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG ("Bioeq") announce that the biologics license application (BLA) for FYB201, Formycon's biosimilar candidate to Lucentis(R), has been recently submitted to the U.S. Food and Drug Administration...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) announced today that it has received the final notification for a grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy in the amount of Euro 12.7 million to support the further development of the COVID-19 drug...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today presented the sales and earnings figures for the first quarter of 2021, demonstrating a positive start to the financial year.

Consolidated sales including other income increased by around EUR 2.2 million to a total of EUR 9.4...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG announce that the marketing authorization application (MAA) for FYB201, Formycon's biosimilar candidate to Lucentis(R) (ranibizumab), has been submitted to the European Medicines Agency...

Munich - Bioeq AG ("Bioeq"), the exclusive owner of the global commercialization rights of FYB201, Formycon's biosimilar candidate to Lucentis(R) (ranibizumab), informed Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), that an exclusive strategic partnership for commercialization of FYB201 in...

Munich - Bioeq AG ("Bioeq"), the exclusive owner of the global commercialization rights of Formycon's biosimilar candidate to Lucentis^(R)1 (ranibizumab), informed Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), that an exclusive strategic partnership for commercialization of FYB201 in...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today published its financial performance indicators for 2020 and has recorded a solid financial year.

On the day of reporting, December 31, 2020, the Formycon Group's commercial figures had developed as forecast. Consolidated group...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced the approval of early action for its COVID-19 drug (FYB207) by the Bavarian Ministry of Economic Affairs, Regional Development and Energy (StMWi). The requested grant is expected to support the further development of FYB207...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), together with its academic partners Prof. Dr. Ulrike Protzer, Chair of Virology, and Prof. Dr. Johannes Buchner, Chair of Biotechnology, Technical University of Munich, today announced new results on the in vitro neutralization of SARS-CoV-2...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and Leukocare AG today announced a collaboration in the area of high-quality biopharmaceuticals.

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") confirm the planned timeline for resubmission of the Biologics License Application ("BLA") for their Lucentis(R) biosimilar candidate FYB201 following a successful pre-BLA interaction with the U.S....

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has received the consent from the Paul-Ehrlich-Institute (PEI) regarding the proposed development concept for its innovative SARS-CoV-2 blocker FYB207. As result of the Scientific Advice, the Federal Institute for Vaccines and Biomedicines...

Munich - Formycon (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that its academic partners of the Technical University of Munich, present results on Formycon's COVID-19 drug (FYB207).

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its Annual General Meeting on December 10, 2020 - for the protection of all persons involved - in virtual form.

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) together with its academic partners Prof. Dr. Ulrike Protzer, Chair of Virology, and Prof. Dr. Johannes Buchner, Chair of Biotechnology, Technical University of Munich, have published results on Formycon's COVID-19-drug (BioRxiv Preprint:

Munich - The Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has extended the appointment of Management Board member Dr. Stefan Glombitza as Chief Operating Officer (COO) until December 31, 2024. With this decision, the supervisory committee is honoring the Formycon manager's...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today announced its figures for the first nine months of the 2020 fiscal year.

Sales and other income of the Formycon Group totaled EUR 23.5 million as of September 30 of this year (prior year period: EUR 26.8 million). Earnings...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and Bioeq GmbH announced the dosage of the first patient in the Phase III clinical trial (first-patient-in). The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its licensing partner Bioeq AG ("Bioeq") announced today that the Biologics License Application (BLA) resubmission strategy for FYB201 has been adjusted.

The approval for FYB201 will be requested directly for a large commercial...

Munich - Against the background of the COVID-19 pandemic, which is set to continue for the foreseeable future, the rules of conduct adopted by the Free State of Bavaria which are still in force, and the objective of avoiding health risks, the Management Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has, with the approval of the company's Supervisory Board on the basis of Article 2 of the law intended to mitigate the consequences of the COVID-19 pandemic in civil, insolvency and criminal proceedings of March 27, 2020, and for the benefit of the health of shareholders, decided to hold the Annual General Meeting (AGM) in a virtual format.

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has received a grant from the Bavarian Research Foundation for the project "Characterization of ACE2-lgG constructs" amounting to Euro 290,000.

SARS-CoV-2 requires the binding of the virus spike protein to the membrane angiotensin...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced the subscription of a cash capital increase by the Active Ownership Group in a private placement. Based on the resolutions of the Management Board and the Supervisory Board, the Company's share capital will be increased by...

Munich - The Management Board of Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) resolved yesterday, with the approval of the Supervisory Board, to increase the company's capital against cash contributions by partially utilizing the approved capital. The Company's share capital of currently EUR...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today announced its financial results for the first half of 2020.

On the day of reporting, June 30, 2020, the Formycon Group's commercial figures developed as forecasted. The Group's turnover which, in addition to the joint-stock...

Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and Bioeq GmbH have today announced the launch of the randomized, double-blind, multi-center phase III study for FYB203, a biosimilar candidate to Eylea®.

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today presented the sales and earnings figures for the first quarter of 2020, demonstrating a positive start to the financial year. By responding early and implementing appropriate measures to protect employees in the context of the COVID-19...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today published its financial performance indicators for 2019 and has recorded a solid financial year.

On the day of reporting, December 31, 2019, the Formycon Group's commercial figures had developed as forecast. Consolidated group...

Munich - In consideration of the current developments of the corona pandemic, Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announces news on its development portfolio.

An early reaction and the implementation of appropriate organizational decentralization measures enabled Formycon to...

Munich - The board of management and the supervisory board of Formycon AG have decided to postpone the general assembly, which was originally scheduled for June 30, 2020 to December 10, 2020. This decision was made in light of the ongoing corona pandemic in order to protect the shareholders,...

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced the start of development of COVID-19 drugs. The company develops biological COVID-19 drugs using its clinically validated antibody-based protein drug technology platform, leveraging computer-aided structural protein design as...

Formycon AG and its licensing partner Bioeq announce today, that the U.S. Food and Drug Administration (FDA) has requested additional data as part of the review process of the BLA for the Lucentis® biosimilar candidate FYB201, submitted by Bioeq in December 2019.

The company's group sales, including other earnings, as of September 30 of this year, amount to EUR 26.8 million while EBITDA was well-balanced and net result totaled around EUR -0.7 million. Formycon Group's stocks of liquid assets, including short-term receivables from deliveries and services as well as other assets are totaling EUR 29.2 million on the day of reporting.

Bioeq IP AG, the exclusive owner of the global commercialization rights of Formycon’s FYB201 has signed a license and development agreement with Coherus BioSciences, Inc. The US Biosimilar-specialist, headquartered in California, will exclusively market and distribute Formycon's biosimilar candidate to Lucentis® (FYB201) in the United States of America (US).

Formycon AG today announced the start of a Phase I clinical trial comparing the pharmacokinetics, safety, and tolerability of FYB202 and the reference product Stelara® (USA / EU). Dosing of study subjects started last week.

Formycon AG has today announced its financial results for the first half of 2019. With a Group turnover of Euro 17,2 million and a period result of Euro -0,7 million Formycon Group's commercial figures were as forcast.

Formycons shareholders followed the proposals of the Board of Management and the Supervisory Board and approved all resolutions proposed by the management with large majorities in each case.

With the agreement dated June 26, 2019, Wendeln & Cie. KG, an asset management company of Mr. Peter Wendeln (anchor shareholder and long-standing member of the Supervisory Board of Formycon AG), acquired all rights from the certificate of subscription as well as the 577,397 shares in Formycon AG from the cash capital increase.

The Group sales, including other earnings, as of March 31 of this year amount to EUR 9.5 million. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 0.5 million. The operating result (EBIT) as well as the quarterly result totaled around EUR 0.2 Million. The reported sales revenues result from reimbursements for development work in the licensed-out projects or projects developed in partnership. For the 2019 fiscal year, revenues in the amount of approximately EUR 35.0 million are expected at the group level.

As of today, totaling EUR 5,000,000.00, have been paid to the company’s capital increase account. The signatory's debt contribution amounting to EUR 12,264,170.30 is therefore still outstanding. The shares have so far not been delivered due to the as yet unsettled payment.

The Group's turnover rose compared to last year (Euro 29 million) by 48 percent to around Euro 43 million, exceeding forecasts. The earnings before interest, tax, depreciation and amortization on fixed and immaterial assets (EBITDA) were Euro 8 million (previous year Euro -0.8 million), which is significantly higher than last year’s figure.

Formycon has published news on its development portfolio. The FDA submission of FYB201 is expected for the beginning of the fourth quarter of this year. The submission to the European Medicines Agency (EMA) is scheduled for the first quarter of 2020. Also significant progress have been achieved with FYB202 and FYB203.

The Swiss company M&H Equity AG from Heerbrugg in the Canton of St. Gallen is a strategic investor with a long-term investment horizon. The funds acquired from the capital increase should be used primarily to develop the company’s own biosimilar products and further increase the value of the pipeline.

Strategic investor M&H Equity AG subscribes for a cash capital increase of € 17,264,170.30 million in the context of a private placement with an issue price of 29.90 EUR per share. The funds acquired from the capital increase will be used primarily to develop the company’s own biosimilar products, particularly FYB205.

For FYB201, new data from the recently completed COLUMBUS-AMD phase III trial in patients with neovascular age-related macular degeneration (nAMD) are available.

The turnover of the Formycon group increased significantly compared with the first nine months of 2017.

Formycon AG has revealed impressive results for the first half of 2018 both in the development of its product candidates and its business figures. Key milestones were reached on project FYB201, a biosimilar candidate for Lucentis®* (ranibizumab).

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars

Formycon has significantly improved its revenue and earnings in the first quarter of 2018 compared to the same period of the previous year.

Formycon has ended the 2017 financial year successfully and has once again significantly advanced the development of its product candidates.

In the COLUMBUS-AMD Trial the primary endpoint has been achieved, thus confirming comparable efficacy between FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).

According to an interim result, the primary endpoint has been achieved in the COLUMBUS-AMD phase III trial, which is intended to demonstrate the efficacy, safety and immunogenicity of FYB201 and the reference medicinal product Lucentis® in patients with neovascular age-related macular degeneration (nAMD).

Formycon has ranked 7th in the FT1000 list compiled by the highly respected business newspaper the Financial Times and data provider Statista, making it the only biotech company to appear in the top ten.

Formycon and Aristo Pharma GmbH, a company of the Struengmann-Group, have formed a joint company for the continued development of FYB202, Formycon's biosimilar candidate for Stelara® (ustekinumab).

Formycon has again progressed well with the further development of its four biosimilars and confirmed the Euro 25 million sales target for whole of 2017.

The Supervisory Board of Formycon has extended the appointments of Dr. Carsten Brockmeyer, board member and CEO, and Dr. Nicolas Combé, board member and CFO, until June 30, 2022.

Formycon has accomplished a successful first half year in 2017. Phase III clinical trial of FYB201 is continuing to progress as planned, the implementation of development cooperation agreement for FYB202 is anticipated for second half of the year

Formycon plans to enter into a co-investment arrangement for its biosimilar candidate FYB202 and aims for a participation of up to 30% in worldwide marketing proceeds.

The commercial performance of Formycon has again advanced as planned in the first quarter of 2017 and the development of its four biosimilar projects has progressed as expected.

Formycon has announced details of a further product from its development pipeline: FYB202 is a biosimilar candidate for Stelara®* (ustekinumab).

Formycon has ended the 2016 financial year successfully and significantly advanced the development of its product candidates.

Formycon plans, with effect from March 1, 2017, to switch to Deutsche Börse AG’s new stock exchange segment “Scale” for small and medium-sized enterprises (SMEs).

Formycon has been named "growth champion 2017" in the category "Chemistry and Pharma" by the news magazine Focus. In the overall ranking, Formycon took second place.

In the first nine months of the 2016 financial year, Formycon has further advanced the development of its drug candidates.

Formycon has been awarded the Research Seal by the Stifterverband in recognition of its innovative research and development work. With this award, the organization is acknowledging the company’s dedication to the development of biosimilars.

The development of Formycon’s biosimilar candidates has progressed well during the first half of 2016. The company announced this update as it unveiled its 2016 half-year figures.

Dr. Stefan Glombitza will join Formycon on October 1, 2016 and add his strengths to the Management Board. He will in future act as Chief Operating Officer (COO), focusing especially on the company's operational development activities

Dr. Carsten Brockmeyer, CEO of Formycon AG, has again been chosen as one of the world’s top 100 most influential people in the pharmaceutical sector by the trade magazine “The Medicine Maker”

The first quarter of 2016 has been successful for Formycon both in operational and financial terms. On the furthest-progressed development project FYB201, a biosimilar candidate for Lucentis®*, the first patient was enrolled in February of this year in the phase III study

Formycon has ended the 2015 financial year with both operational and financial success. In the last year, Formycon has made great strides with the initiation of the clinical Phase III study involving the biosimilar candidate FYB201 (ranibizumab) in particular.

Formycon AG has announced details on the second biosimilar product which is jointly developed with Santo Holding GmbH. FYB203 is a biosimilar candidate for Eylea® (aflibercept).

Formycon AG, Munich, and bioeq GmbH, Holzkirchen, have enrolled the first patient in their clinical Phase III study involving FYB201, Formycon’s biosimilar version of Lucentis®

Formycon appoints Johannes Buchner, professor in Biotechnology at the Technical University of Munich, and President of the German Society for Biochemistry and Molecular Biology (GBM), to its Advisory Board

Formycon today announced that it has filed already three patent applications relating to the formulation and intraocular delivery of VEGF antagonists.

Formycon has announced a significant increase in its revenue for the first nine months of this year, thus continuing on its path of profitable growth.

Formycon AG, Munich, Germany, and bioeq GmbH, Holzkirchen, Germany, announced the initiation of a pivotal Phase III clinical trial with FYB201, an investigational biosimilar ranibizumab (Lucentis®)

Formycon has closed the first half of its fiscal year 2015 with successful financial results. Consolidated revenue for the period ending June 30, 2015, was EUR 9.8 million. Net income for the six-month period was EUR 1.53 million.

Formycon AG has received a scientific advice letter from the U.S. Food and Drug Administration (FDA) regarding the preclinical and clinical development program for FYB201, the first biosimilar product candidate to emerge from its development pipeline, following the receipt of similarly favorable scientific advice from the European Medicines Agency (EMA) in December 2014.

In the first quarter of 2015, Formycon reported consolidated revenues of EUR 3.0 million. Based upon the recently announced successful signing of a partnership deal for FYB203, the company has raised its full-year forecast for fiscal year 2015, which it now expects to end with positive EBITDA.

Under the agreement, Santo Holding will assume responsibility for, and the costs of, all further development activities, production and marketing of the Formycon biosimilar drug. Based on sales projections, the agreement is expected to yield Formycon total cumulative revenue well over the hundred million euro mark.

He appears on the list alongside global leaders from the industry, including CEOs, Nobel Prize winners, and many other celebrated scientists from the pharmaceutical world.

The Supervisory Board of Formycon AG has unanimously voted to extend the executive board appointment of Dr. Nicolas Combé, the co-founder of the company who has served with distinction as its chief financial officer since May 5, 2010.

Proceeds from the share placement in the gross amount of EUR 11,115,960.00 will flow entirely to the company and are to be used to advance and expand the company’s biosimilar development programs in accordance with its plans, thus further strengthening the market position which Formycon has already achieved.

Formycon AG has reported its preliminary consolidated financial results for fiscal year 2014, with sales revenue and other income totaling EUR 12.67 million (prior year: EUR 0.41 million). EBITDA for the year was EUR 1.94 million (prior year: - EUR 6.64 million), while net income came in at EUR 0.86 million (prior year: - EUR 7.74 million).

This achievement is another important step in Formycon’s preparation of the pivotal phase III study of clinical testing for its first biosimilar candidate (FYB201).

For Formycon AG, the favorable response to its proposed plan for clinical studies means a significant shortening of its development and approval schedule.

For the first nine months of 2014, the company posted revenues of EUR 8.98 million (2013: EUR 0.33 million). Its operating profitability likewise improved markedly, with EBITDA of EUR 2.64 million for the period from January through the end of September.

In the first half of 2014, Formycon AG recorded a turnover of 7.4 million euros (2013: 0.2 million euros). The company's EBITDA amounted to 3.2 million euros in the first half of 2014 (first half of 2013: -3.0 million euros). Overall, the company expects to achieve positive EBITDA for the business year 2014.

These products will be part of the so-called “third wave” of biosimilars, referring to the major, multi-billion-dollar blockbuster drugs created through biotechnology for indications in the areas of ophthalmology, autoimmune...

For the first quarter of this year, Formycon AG has reported strong top-line and bottom-line growth, with revenue of EUR 5.832.904 compared to EUR 7.886 in the prior-year period.

Increased marketing potential for Formycon's first biosimilar FYB201 gives reason to expect a greater turnover share for Formycon.

Over the past 20 years, Dr. Bernhard Hampl was a successful CEO in large American generics companies such as EON LABS Inc. and later Sandoz US, which after fusion of the two companies became America's second-largest manufacturer...

Formycon sets course for long-term alignment as a global biosimilar developer. Dr. Carsten Brockmeyer, one of the world's leading biosimilar experts, joined the board of directors. In addition Formycon appointed Dr. Gerhard Schaefer, former Head of Global Product and Business Development at Sandoz International, and Simon Sturge, previously Corporate Senior Vice President at Boehringer Ingelheim, to the advisory board.

Munich – Formycon AG today announced the signing of an exclusive, worldwide licensing agreement with Santo Holding GmbH, owned by the well noted German pharmaceutical investors Andreas and Thomas Strüngmann, granting rights to the first biosimilar drug of Formycon’s development pipeline.

Successful placement of shares among international institutional investores and family offices. The gross proceeds to the company of EUR 9,43 will be used to fund further product development activities.

Gerhard Schaefer graduated with a Ph.D. in Chemistry from Stuttgart University. During his more than 30 years in the generic pharmaceutical industry, he held increasing senior management positions in development, quality assurance / control and business development at Azupharma, Knoll, Stada, HEXAL and Sandoz.